Lv32
234 积分 2021-12-13 加入
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
1天前
已完结
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
25天前
已完结
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
29天前
已完结
Ibrutinib and venetoclax combination therapy for mantle cell lymphoma: are two better than one?
1个月前
已完结
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
1个月前
已完结
Front‐line management of indolent non‐Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma
1个月前
已完结
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis
1个月前
已完结
Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma
1个月前
已关闭
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
1个月前
已完结
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
1个月前
已完结
皖公网安备34019202002308
